Mizuho initiated coverage of Verastem with a Neutral rating and $2 price target. The analyst says the company’s valuation expansion rests on confirmation of an accelerated approval path for avutometinib plus defactinib as well as clinical evidence of avutometinib combinations to treat KRASG12C non-small-cell-lung-cancer. Given the "nearer term riskiness" of the KRASG12C programs and the longer time horizon to LGSOC filing, the firm thinks investors "have time before becoming involved in the shares."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VSTM: